Valneva SE announced that the European Commission has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA 2001, for use as primary vaccination in people from 18 to 50 years of age.
Pfizer Inc.and BioNTech SE announced they will submit a request to the FDA for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT 162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020.
The nonprofit Infectious Disease Research Institute has commenced the world's first clinical trial of a vaccine against Leishmaniasis. The vaccine,...
Swedish Orphan Biovitrum AB (publ) (Sobi) and Selecta Biosciences, Inc. announced the commencement of the phase III clinical programme of SEL 212 for chronic refractory gout, with the randomisation of the first patient in the study.
Ariad Pharma and Otsuka Pharmaceutical Co., Ltd. announced that they have entered into an agreement for Otsuka to commercialize Iclusig...
Pfizer and BioNTech SE announced a 30 microgram booster dose of their Omicron BA.1- Bivalent COVID-19 Vaccine (Comirnaty Original/Omicron BA.1 15/15 microg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals 12 years and older.
Pfizer Canada and BioNTech SE announced the initiation of a rolling submission to Health Canada for BNT 162b2, the lead candidate from the companies' vaccine development program against COVID-19.
Pfizer and BioNTech SE announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains.
Valneva SE announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine candidate
Valneva SE a specialty vaccine company, announced that the FDA has revised the Prescription Drug User Fee Act (PDUFA) action date for the Biologics License Application (BLA) for VLA 1553, Valneva’s chikungunya virus vaccine candidate, from the previously communicated end of August to the end of November